Reaction
Nasal Turbinate Hypertrophy reporting signals
As of the last recalculation, Nasal Turbinate Hypertrophy appears in 371 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 248.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciclesonide | 52 | 248.9 | 249.9 |
| Theophylline Anhydrous | 47 | 243.4 | 244.3 |
| Theophylline | 41 | 224.9 | 225.7 |
| Fluticasone Furoate | 26 | 129.4 | 129.7 |
| Esomeprazole Magnesium Capsule, Delayed Release | 27 | 112.5 | 112.7 |
| Esomeprazole Magnesium Delayed Release Capsules | 27 | 112.5 | 112.7 |
| Esomeprazole Magnesium Dihydrate | 27 | 112.0 | 112.2 |
| Ipratropium Bromide | 57 | 105.7 | 105.9 |
| Doxepin Hydrochloride | 20 | 93.9 | 94.0 |
| Doxepin | 16 | 92.5 | 92.7 |
| Duloxetine | 76 | 76.7 | 76.8 |
| Valsartan And Hydrochlorothiazide | 17 | 73.6 | 73.7 |
| Valsartan Oral | 52 | 62.3 | 62.4 |
| Cetirizine Hydrochloride Allergy | 29 | 58.2 | 58.2 |
| Cetirizine Hydrochloride Tablets | 29 | 58.2 | 58.2 |
| Esomeprazole | 48 | 49.7 | 49.8 |
| Fluticasone Propionate And Salmeterol Xinafoate | 46 | 48.9 | 48.9 |
| Conjugated Estrogens | 34 | 35.9 | 35.9 |
| Azelastine | 11 | 35.4 | 35.4 |
| Estrogens, Conjugated | 34 | 35.3 | 35.3 |
| Ranitidine Hydrochloride | 20 | 21.8 | 21.8 |